Vaccinations

University of Oxford launches first human aerosol TB vaccine trial

The University of Oxford has commenced a new clinical trial called TB-45, which will test the safety of a new tuberculosis (TB) vaccine.

Digital tech in response to the COVID-19 pandemic

Justin Nogarede, FEPS Digital Policy Analyst, says that while digital tech can’t solve everything, can it solve anything? Read on to find out about the role of digital tech in the COVID-19 pandemic.

Moderna say COVID vaccine 100% effective in 12-17 year olds

The Moderna vaccine has been found to be 100% effective against COVID-19 in 12-17 year olds, according to new data from the TeenCOVE study.

PHE say one dose of vaccine 33.5% effective against Indian variant

Public Health England have found that both Pfizer and AstraZeneca vaccines against the Indian variant would have an efficacy of 33.5% in one dose.

COVID patients have antibodies “11 months after first symptoms”

Scientists are explaining that antibody production doesn't stop, it simply plateaus - in some people, COVID antibodies exist "11 months after first symptoms".

Parliament and Council agree on EU Digital COVID Certificate proposal

The European Parliament and the Council have reached an agreement on the Commission's proposal of the EU Digital COVID Certificate.

Commission signs third contract for 1.8 billion BioNTech-Pfizer doses

The European Commission has announced that it has signed a third contract to secure an additional 1.8 billion BioNTech-Pfizer vaccine doses.

Logistics & supply chain will win the COVID-19 war

Professor Richard Wilding argues that biochemistry is winning the battle against coronavirus, but logistics and supply chain will win the war.

EU4Health: Building healthcare systems of tomorrow

European Commission Director General for Health and Food Safety Sandra Gallina details the ambitious EU4Health Programme proposed as a response to COVID-19.

COVID-19 and its impact on society

European Public Health Association Executive Director, Dineke Zeegers Paget, updates us about COVID-19 and its impact on society, public health, healthcare and equitable access to vaccines.

Pfizer vaccine produces greater antibody response when given at 12 weeks

A new study has found that the second dose of the Pfizer vaccine produces a 3.5-times greater antibody response when given at 12 weeks, compared to three weeks.

Pfizer vaccine can be given to 12-15 year olds in US

On Wednesday (12 May), the CDC announced that the Pfizer vaccine could now be given to 12-15 year olds - effective immediately for 17 million adolescents.

Communication strategies are critical for vaccine rollout

Adam Enterkin, Global SVP Sales at BlackBerry, explores the critical role of secure crisis communications for the vaccine rollout and the value of a communication strategy to combat misinformation.

Study examines immune responses to COVID in patients with antibody deficiencies

A new study aims to explore the immune response to COVID-19 infection and vaccination in patients with antibody deficiencies.

Why COVID vaccine development was exceptionally speedy

Ram May-Ron, Managing Partner at FreeMind Group, explains why COVID vaccine development was exceptionally speedy.

COVID-19 vaccine does not damage placentas

Researchers from Northwestern Medicine have studied the placentas from patients who received the COVID-19 vaccine during pregnancy and found no evidence of damage.

Immune system research: Vaccines and immunotherapeutics

Dr Babita Agrawal, Professor at the University of Alberta, discusses both the vital present and future roles of vaccines and immunotherapeutics in combatting COVID-19.

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders